Particulars | Q4FY24 | Q4FY23 | YoY % | Q3FY24 | QoQ% |
---|---|---|---|---|---|
Total revenue from operations | 1068.00 | 898.00 | 19.00% | 759.00 | 41.00% |
EBIDTA | 497.00 | 339.00 | 47.00% | 268.00 | 85.00% |
EBIDTA Margin % | 47.00% | 38.00% | 877 bps | 35.00% | 1119 bps |
PAT | 386.00 | 276.00 | 40.00% | 213.00 | 82.00% |
EPS (Rs.) | 21.56 | 15.11 | 43.00% | 11.88 | 81.00% |
Source: Company Filings; stockaxis Research
Q4FY24 Result Highlights
Natco Pharma Ltd (NPL) experienced a strong Q4FY24, largely due to significant traction
from the anti-cancer drug gRevlimid. Revenues increased by ~19% YoY to Rs 1068 crore,
with export formulations rising by 35% to Rs 955 crore, primarily driven by gRevlimid.
Typically, sales of gRevlimid are higher in Q4 and Q1. Other segments, however,
remained weak, with API segmentdeclining by 31% to Rs 50 crore and domestic formulations
registered a degrowth by 43% to Rs 52.4 crore. EBITDA grew by 47% YoY to Rs 449
crore, with margins improving by 877 basis points, mainly due to Revlimid sales.
The improvement in gross profit margins up 1541 bps YoY to 86.5% also contributed
to the EBITDA growth. Consequently, PAT increased by 40% year-on-year to Rs 213
crore.
The company’s Total Formulations business saw a 25.8% YoY growth to Rs 1007 crores, driven by a low base in the export sector. The management anticipates a 15-18% growth in Domestic Pharma for FY25. Crop Protection sales increased to Rs 25 crores bolstered by a ramp-up in CTPR sales. Additionally, they plan to launch 2-3 unique products over the next 12-18 months. The Export Formulations business grew by 34.6% YoY to Rs 950 crores, primarily due to Revlimid. The Rest of World (RoW) markets, including Brazil and Canada, performed well, generating revenues of Rs 2.6 crores and CAD 40 million, respectively.
Financial
Business
Outlook & ValuationTop of Form
Natco Pharma Ltd has achieved robust revenue and PAT growth in FY24, The company is focusing on expanding its presence in both domestic and international markets. Natco’s focus on strengthening the core business is bearing fruit, evident from steady India and Agrochem ramp-up (25% growth potential). gRevlimid opportunity is turning out well, and increased investment in R&D has led to a robust US pipeline—semaglutide, olaparib, erdafitinib, etc. Agrochem is starting to show traction and domestic business is complemented by new launches. We welcome the R&D ramp-up (from 8% to 10% of revenue) given Natco’s strength in complex generics. The strong Balance Sheet provides ample scope to pursue inorganic opportunities. With base business recovering and Natco pursuing complex opportunities with gRevlimid, long term outlook appears promising. Management also sounds confident and has guided for 15-20% sales growth and 20% PAT growth in FY25 thus, reaffirms its bullish stance. At a CMP of Rs. 1010, the stock is trading at 12x FY26E. We recommend a HOLD rating on the stock.
Particulars | Q4FY24 | Q4FY23 | YoY % | Q3FY24 | QoQ% |
---|---|---|---|---|---|
Total revenue from operations | 1068.00 | 898.00 | 19.00% | 759.00 | 41.00% |
COGS | 143.00 | 258.00 | -45.00% | 162.00 | -12.00% |
Gross profit | 926.00 | 640.00 | 45.00% | 596.00 | 55.00% |
Gross profit margin | 87.00% | 71.00% | 1541 bps | 79.00% | 801 bps |
Employee cost | 143.00 | 119.00 | 20.00% | 122.00 | 17.00% |
Other exp | 286.00 | 182.00 | 58.00% | 206.00 | 39.00% |
EBIDTA | 497.00 | 339.00 | 47.00% | 268.00 | 85.00% |
EBIDTA Margin % | 47.00% | 38.00% | 877 bps | 35.00% | 1119 bps |
Depreciation exp | 56.00 | 41.00 | 35.00% | 44.00 | 26.00% |
EBIT | 442.00 | 298.00 | 48.00% | 224.00 | 97.00% |
Finance cost | 6.00 | 3.00 | 130.00% | 5.00 | 35.00% |
Other income | 42.00 | 29.00 | 45.00% | 37.00 | 14.00% |
PBT | 477.00 | 324.00 | 47.00% | 256.00 | 86.00% |
Tax | 91.00 | 49.00 | 88.00% | 44.00 | 109.00% |
PAT | 386.00 | 276.00 | 40.00% | 213.00 | 82.00% |
PAT Margin | 36.00% | 31.00% | 543 bps | 28.00% | 810 bps |
EPS (Rs.) | 21.56 | 15.11 | 43.00% | 11.88 | 81.00% |